• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2022 Fiscal Year Final Research Report

Competitive linear ubiquitin binding in NFkB-signaling

Research Project

  • PDF
Project/Area Number 20K15756
Research Category

Grant-in-Aid for Early-Career Scientists

Allocation TypeMulti-year Fund
Review Section Basic Section 43040:Biophysics-related
Research InstitutionKyoto University

Principal Investigator

WALINDA Erik  京都大学, 医学研究科, 助教 (80782391)

Project Period (FY) 2020-04-01 – 2023-03-31
Keywordsubiquitin / ubiquitin binding / NZF domain / M1 ubiquitin chains / linear ubiquitin chains / NMR spectroscopy / ITC / MD simulations
Outline of Final Research Achievements

In these two yearsl our research has proceeded rather smoothly. We were able to publish several aspects of this project in various international peer-reviewed journals.

The project focuses on protein ubiquitylation, attaching ubiquitin to target proteins. Initially, it studied K48-linked polyubiquitin chains for degradation. The discovery of linear ubiquitin chains and LUBAC's role in immune signaling necessitated understanding them further. The study aims to explore HOIL-1L's binding specificity to linear ubiquitin chains, conformational changes, preference for M1-linked polyubiquitin, and its role in HOIL-1L and LUBAC. Key findings include optimized purification of LUBAC fragments for cancer drug screening, investigating cyclization's impact on ubiquitin chain recognition by OTUB1, and examining linear ubiquitin recognition by HOIL-1L NZF domain. These results enhance understanding of linear ubiquitin binding and the ubiquitin code.

Free Research Field

生物物理学

Academic Significance and Societal Importance of the Research Achievements

Scientific significance: understanding non-proteolytic functions of ubiquitin chains, particularly in immune signaling, survival, inflammation, immune disorders, cancer, and infectious diseases.

Social significance: potential to contribute to the development of treatments for immune disorders.

URL: 

Published: 2024-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi